Cargando…

Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits

BACKGROUND: Procyanidins have beneficial effects on metabolic syndrome and antimicrobial activity, but the mechanisms underlying these effects are unclear. AIM: To investigate the effects of procyanidin B2 (PB2) on non-alcoholic fatty liver disease and to explore the possible mechanism. METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Ya-Wei, Lei, Guang-Tao, Wu, Qing-Hua, Jiang, Yu, Huang, Man-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397725/
https://www.ncbi.nlm.nih.gov/pubmed/30833801
http://dx.doi.org/10.3748/wjg.v25.i8.955
_version_ 1783399450421493760
author Xing, Ya-Wei
Lei, Guang-Tao
Wu, Qing-Hua
Jiang, Yu
Huang, Man-Xiang
author_facet Xing, Ya-Wei
Lei, Guang-Tao
Wu, Qing-Hua
Jiang, Yu
Huang, Man-Xiang
author_sort Xing, Ya-Wei
collection PubMed
description BACKGROUND: Procyanidins have beneficial effects on metabolic syndrome and antimicrobial activity, but the mechanisms underlying these effects are unclear. AIM: To investigate the effects of procyanidin B2 (PB2) on non-alcoholic fatty liver disease and to explore the possible mechanism. METHODS: Thirty male New Zealand white rabbits were randomized into three groups. All of them were fed either a high-fat-cholesterol diet (HCD) or chow diet. HCD-fed rabbits were treated with vehicle or PB2 daily for 12 wk. Body weight and food intake were evaluated once a week. Serum biomarkers, such as total cholesterols, triglycerides, and aspartate transaminase, were detected. All rabbits were sacrificed and histological parameters of liver were assessed by hematoxylin and eosin-stained sections. Moreover, several lipogenic genes and gut microbiota (by 16S rRNA sequencing) were investigated to explore the possible mechanism. RESULTS: The HCD group had higher body weight, liver index, serum lipid profile, insulin resistance, serum glucose, and hepatic steatosis compared to the CHOW group. PB2 treatment prevented HCD-induced increases in body weight and hypertriglyceridemia in association with triglyceride accumulation in the liver. PB2 also ameliorated low-grade inflammation, which was reflected by serum lipopolysaccharides and improved insulin resistance. In rabbit liver, PB2 prevented the upregulation of steroid response element binding protein 1c and fatty acid synthase and the downregulation of carnitine palmitoyltransferase, compared to the HCD group. Moreover, HCD led to a decrease of Bacteroidetes in gut microbiota. PB2 significantly improved the proportions of Bacteroidetes at the phylum level and Akkermansia at the genus level. CONCLUSION: Our results indicate the possible mechanism of PB2 to improve HCD-induced features of metabolic syndrome and provide a new dietary supplement.
format Online
Article
Text
id pubmed-6397725
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-63977252019-03-04 Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits Xing, Ya-Wei Lei, Guang-Tao Wu, Qing-Hua Jiang, Yu Huang, Man-Xiang World J Gastroenterol Basic Study BACKGROUND: Procyanidins have beneficial effects on metabolic syndrome and antimicrobial activity, but the mechanisms underlying these effects are unclear. AIM: To investigate the effects of procyanidin B2 (PB2) on non-alcoholic fatty liver disease and to explore the possible mechanism. METHODS: Thirty male New Zealand white rabbits were randomized into three groups. All of them were fed either a high-fat-cholesterol diet (HCD) or chow diet. HCD-fed rabbits were treated with vehicle or PB2 daily for 12 wk. Body weight and food intake were evaluated once a week. Serum biomarkers, such as total cholesterols, triglycerides, and aspartate transaminase, were detected. All rabbits were sacrificed and histological parameters of liver were assessed by hematoxylin and eosin-stained sections. Moreover, several lipogenic genes and gut microbiota (by 16S rRNA sequencing) were investigated to explore the possible mechanism. RESULTS: The HCD group had higher body weight, liver index, serum lipid profile, insulin resistance, serum glucose, and hepatic steatosis compared to the CHOW group. PB2 treatment prevented HCD-induced increases in body weight and hypertriglyceridemia in association with triglyceride accumulation in the liver. PB2 also ameliorated low-grade inflammation, which was reflected by serum lipopolysaccharides and improved insulin resistance. In rabbit liver, PB2 prevented the upregulation of steroid response element binding protein 1c and fatty acid synthase and the downregulation of carnitine palmitoyltransferase, compared to the HCD group. Moreover, HCD led to a decrease of Bacteroidetes in gut microbiota. PB2 significantly improved the proportions of Bacteroidetes at the phylum level and Akkermansia at the genus level. CONCLUSION: Our results indicate the possible mechanism of PB2 to improve HCD-induced features of metabolic syndrome and provide a new dietary supplement. Baishideng Publishing Group Inc 2019-02-28 2019-02-28 /pmc/articles/PMC6397725/ /pubmed/30833801 http://dx.doi.org/10.3748/wjg.v25.i8.955 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Basic Study
Xing, Ya-Wei
Lei, Guang-Tao
Wu, Qing-Hua
Jiang, Yu
Huang, Man-Xiang
Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits
title Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits
title_full Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits
title_fullStr Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits
title_full_unstemmed Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits
title_short Procyanidin B2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits
title_sort procyanidin b2 protects against diet-induced obesity and non-alcoholic fatty liver disease via the modulation of the gut microbiota in rabbits
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397725/
https://www.ncbi.nlm.nih.gov/pubmed/30833801
http://dx.doi.org/10.3748/wjg.v25.i8.955
work_keys_str_mv AT xingyawei procyanidinb2protectsagainstdietinducedobesityandnonalcoholicfattyliverdiseaseviathemodulationofthegutmicrobiotainrabbits
AT leiguangtao procyanidinb2protectsagainstdietinducedobesityandnonalcoholicfattyliverdiseaseviathemodulationofthegutmicrobiotainrabbits
AT wuqinghua procyanidinb2protectsagainstdietinducedobesityandnonalcoholicfattyliverdiseaseviathemodulationofthegutmicrobiotainrabbits
AT jiangyu procyanidinb2protectsagainstdietinducedobesityandnonalcoholicfattyliverdiseaseviathemodulationofthegutmicrobiotainrabbits
AT huangmanxiang procyanidinb2protectsagainstdietinducedobesityandnonalcoholicfattyliverdiseaseviathemodulationofthegutmicrobiotainrabbits